TKangWM的个人主页 - 老虎社区

TKangWM

TKangWM

暂无个人介绍

IP属地：未知

33关注

2粉丝

0主题

0勋章

2021-11-09

$XPeng Inc.(XPEV)$💡

2021-11-09

$Merck(MRK)$Getting better

2021-11-07

👍

Will Pfizer Outgun Merck With Oral COVID-19 Pill?

2021-11-04

👍

U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill

2021-11-04

$XPeng Inc.(XPEV)$[What]

2021-11-02

$XPeng Inc.(XPEV)$Upup

2021-11-02

$Merck(MRK)$[Angry]

2021-11-02

$Merck(MRK)$👌

2021-11-01

👍

@华商韬略:市值观察丨最强“她经济”！超级风口肥了谁？

2021-11-01

$Merck(MRK)$[Miser] [Miser]

2021-11-01

😀

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3582197285087556,"uuid":"3582197285087556","gmtCreate":1619163402203,"gmtModify":1619687045433,"name":"TKangWM","pinyin":"tkangwm","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":33,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.14","exceedPercentage":"93.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"93.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":844363742,"gmtCreate":1636389621581,"gmtModify":1636389621685,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>💡","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>💡","text":"$XPeng Inc.(XPEV)$💡","images":[{"img":"https://static.tigerbbs.com/a1471afc007482b8724af2ef832db820","width":"1125","height":"3067"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844363742","isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844363595,"gmtCreate":1636389582324,"gmtModify":1636389582438,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Getting better","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Getting better","text":"$Merck(MRK)$Getting better","images":[{"img":"https://static.tigerbbs.com/fa6d0bd296fa0b17edd77915a1de0bd1","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844363595","isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845053489,"gmtCreate":1636255882226,"gmtModify":1636255882323,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845053489","repostId":"1152406340","repostType":2,"repost":{"id":"1152406340","pubTimestamp":1636157546,"share":"https://www.laohu8.com/m/news/1152406340?lang=&edition=full","pubTime":"2021-11-06 08:12","market":"us","language":"en","title":"Will Pfizer Outgun Merck With Oral COVID-19 Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152406340","media":"Benzinga","summary":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy ","content":"<p><b>Merck, Inc.</b>&nbsp;is locking horns with peer&nbsp;<b>Pfizer, Inc.</b>&nbsp;in what could be termed as the battle supremacy in the COVID-19 treatment market.</p>\n<p>The stakes are high, with&nbsp;an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.</p>\n<p><b>Pfizer Dips Into COVID-19 Treatment Arena:</b>After acing the&nbsp;COVID-19 vaccine race&nbsp;along with its German partner&nbsp;<b>BioNTech SE</b>, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.</p>\n<p>The company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.</p>\n<p>The positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.</p>\n<p>Merck had its share of upside in early October when it reported positive Phase 3 data for an&nbsp;oral COVID-19 pill,&nbsp;molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.</p>\n<p>These two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.</p>\n<p><b>Pfizer Vs. Merck Data Comparison:</b>As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.</p>\n<p>Only about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.</p>\n<p>Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.</p>\n<p>Merck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.</p>\n<p>Through day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight&nbsp;deaths in patients who received placebo.</p>\n<p>Not only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.</p>\n<p>\"Between&nbsp;<b>Roche Holding AG's</b>&nbsp;recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.</p>\n<p><b>Authorization Before Year-End?</b>At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.</p>\n<p>It plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.</p>\n<p>BofA expects the application to be soon submitted to the FDA, with&nbsp;an authorization likely&nbsp;by the end of the year.</p>\n<p>Meanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.</p>\n<p>Its application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.</p>\n<p>The commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.</p>\n<p>Meanwhile,&nbsp;<b>Gilead, Inc.'s</b>&nbsp;antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.</p>\n<p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Pfizer Outgun Merck With Oral COVID-19 Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Pfizer Outgun Merck With Oral COVID-19 Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 08:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152406340","content_text":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.\nPfizer Dips Into COVID-19 Treatment Arena:After acing the COVID-19 vaccine race along with its German partner BioNTech SE, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.\nThe company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.\nThe positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.\nMerck had its share of upside in early October when it reported positive Phase 3 data for an oral COVID-19 pill, molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.\nThese two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.\nPfizer Vs. Merck Data Comparison:As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.\nOnly about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.\nSimilar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.\nMerck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.\nThrough day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight deaths in patients who received placebo.\nNot only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.\n\"Between Roche Holding AG's recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.\nAuthorization Before Year-End?At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.\nIt plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.\nBofA expects the application to be soon submitted to the FDA, with an authorization likely by the end of the year.\nMeanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.\nIts application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.\nThe commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.\nMeanwhile, Gilead, Inc.'s antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846032515,"gmtCreate":1636034485136,"gmtModify":1636034587425,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846032515","repostId":"1167697278","repostType":2,"repost":{"id":"1167697278","pubTimestamp":1636025569,"share":"https://www.laohu8.com/m/news/1167697278?lang=&edition=full","pubTime":"2021-11-04 19:32","market":"us","language":"en","title":"U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1167697278","media":"Bloomberg","summary":"Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s ","content":"<p>Britain became the first country to approve Merck &amp; Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.</p>\n<p>The U.K.’s Medicines and Healthcare products Regulatory Agency authorized the drug, molnupiravir, for use in people with mild to moderate Covid and at least one risk factor for developing severe illness, the regulator said in a statement Thursday.</p>\n<p>Merck shares rose 2% in premarket U.S. trading.</p>\n<p><img src=\"https://static.tigerbbs.com/228503f62c7823fd2b8b78316babd5e6\" tg-width=\"847\" tg-height=\"622\" width=\"100%\" height=\"auto\"></p>\n<p>Boris Johnson’s government plans to focus on antiviral treatments at the same time as rolling out boosters to bolster immunity levels as winter approaches. The U.K. has already announced deals to secure two new Covid treatments: 480,000 courses of Merck’s pill and 250,000 courses of Pfizer Inc.’s PF 07321332/ritonavir.</p>\n<p>Coronavirus infections in England reached their highest level yet in October, based on a large study published Thursday. While hospitalizations and deaths remained low, the React-1 study led by Imperial College London recorded the highest prevalence of cases since the research began in May 2020. Covid infections among study participants increased to 1.72%, or one in 58 people, more than double the level in the previous month’s report.</p>\n<p>Based on the clinical trial data, Merck’s pill is most effective when taken during the early stages of infection, the regulator said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.K. Drug Regulator Is First to Approve Merck’s Covid-19 Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 19:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.\nThe U.K.’s Medicines and Healthcare ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-04/u-k-drug-regulator-is-first-to-approve-merck-s-covid-19-pill?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167697278","content_text":"Britain became the first country to approve Merck & Co’s Covid-19 antiviral pill, with the nation’s drug regulator describing the treatment as safe and effective.\nThe U.K.’s Medicines and Healthcare products Regulatory Agency authorized the drug, molnupiravir, for use in people with mild to moderate Covid and at least one risk factor for developing severe illness, the regulator said in a statement Thursday.\nMerck shares rose 2% in premarket U.S. trading.\n\nBoris Johnson’s government plans to focus on antiviral treatments at the same time as rolling out boosters to bolster immunity levels as winter approaches. The U.K. has already announced deals to secure two new Covid treatments: 480,000 courses of Merck’s pill and 250,000 courses of Pfizer Inc.’s PF 07321332/ritonavir.\nCoronavirus infections in England reached their highest level yet in October, based on a large study published Thursday. While hospitalizations and deaths remained low, the React-1 study led by Imperial College London recorded the highest prevalence of cases since the research began in May 2020. Covid infections among study participants increased to 1.72%, or one in 58 people, more than double the level in the previous month’s report.\nBased on the clinical trial data, Merck’s pill is most effective when taken during the early stages of infection, the regulator said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848315844,"gmtCreate":1635967406960,"gmtModify":1635967407046,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>[What]&nbsp;","text":"$XPeng Inc.(XPEV)$[What]","images":[{"img":"https://static.tigerbbs.com/00698f2c640d8a3ddb153350c4465240","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848315844","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843715943,"gmtCreate":1635858635247,"gmtModify":1635858635247,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>Upup","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>Upup","text":"$XPeng Inc.(XPEV)$Upup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843715943","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843712920,"gmtCreate":1635858543784,"gmtModify":1635858543784,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Angry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Angry]&nbsp;","text":"$Merck(MRK)$[Angry]","images":[{"img":"https://static.tigerbbs.com/ea2b628412d7c17480ae0ab07cc7014d","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843712920","isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843716246,"gmtCreate":1635858494280,"gmtModify":1635858494280,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>👌","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>👌","text":"$Merck(MRK)$👌","images":[{"img":"https://static.tigerbbs.com/ad18d7da2125956cccdcd353332ec8df","width":"1125","height":"3083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843716246","isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849842735,"gmtCreate":1635745760453,"gmtModify":1635745760453,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849842735","repostId":"840102207","repostType":1,"repost":{"id":840102207,"gmtCreate":1635598740000,"gmtModify":1635601193973,"author":{"id":"3524105760314666","authorId":"3524105760314666","name":"华商韬略","avatar":"https://static.tigerbbs.com/fbcbbcdfdd125576e4d9038a38b0dc86","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"市值观察丨最强“她经济”！超级风口肥了谁？","htmlText":"作 者 / 文 雨 图片：网络、图虫创意 &nbsp; 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","listText":"作 者 / 文 雨 图片：网络、图虫创意 &nbsp; 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","text":"作 者 / 文 雨 图片：网络、图虫创意 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","images":[{"img":"https://static.tigerbbs.com/1c06c03b7f3a46da8abbb2ef9e86d8a9","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/bb9d2414aeb240d38a1c9ccca1e3c0bf","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/8dd9ef57d2184ee4b4ab6f96012d242f","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840102207","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849842859,"gmtCreate":1635745725267,"gmtModify":1635745725267,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Miser]&nbsp;[Miser]&nbsp;","text":"$Merck(MRK)$[Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c066cfaf8b4b464ede18b3861c3949ca","width":"1125","height":"2992"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849842859","isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849846435,"gmtCreate":1635745671828,"gmtModify":1635745671915,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849846435","repostId":"2179229343","repostType":2,"isVote":1,"tweetType":1,"viewCount":399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":846032515,"gmtCreate":1636034485136,"gmtModify":1636034587425,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846032515","repostId":"1167697278","repostType":2,"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843712920,"gmtCreate":1635858543784,"gmtModify":1635858543784,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Angry]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Angry]&nbsp;","text":"$Merck(MRK)$[Angry]","images":[{"img":"https://static.tigerbbs.com/ea2b628412d7c17480ae0ab07cc7014d","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843712920","isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844363742,"gmtCreate":1636389621581,"gmtModify":1636389621685,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>💡","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>💡","text":"$XPeng Inc.(XPEV)$💡","images":[{"img":"https://static.tigerbbs.com/a1471afc007482b8724af2ef832db820","width":"1125","height":"3067"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844363742","isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844363595,"gmtCreate":1636389582324,"gmtModify":1636389582438,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Getting better","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>Getting better","text":"$Merck(MRK)$Getting better","images":[{"img":"https://static.tigerbbs.com/fa6d0bd296fa0b17edd77915a1de0bd1","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844363595","isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845053489,"gmtCreate":1636255882226,"gmtModify":1636255882323,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845053489","repostId":"1152406340","repostType":2,"repost":{"id":"1152406340","pubTimestamp":1636157546,"share":"https://www.laohu8.com/m/news/1152406340?lang=&edition=full","pubTime":"2021-11-06 08:12","market":"us","language":"en","title":"Will Pfizer Outgun Merck With Oral COVID-19 Pill?","url":"https://stock-news.laohu8.com/highlight/detail?id=1152406340","media":"Benzinga","summary":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy ","content":"<p><b>Merck, Inc.</b>&nbsp;is locking horns with peer&nbsp;<b>Pfizer, Inc.</b>&nbsp;in what could be termed as the battle supremacy in the COVID-19 treatment market.</p>\n<p>The stakes are high, with&nbsp;an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.</p>\n<p><b>Pfizer Dips Into COVID-19 Treatment Arena:</b>After acing the&nbsp;COVID-19 vaccine race&nbsp;along with its German partner&nbsp;<b>BioNTech SE</b>, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.</p>\n<p>The company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.</p>\n<p>The positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.</p>\n<p>Merck had its share of upside in early October when it reported positive Phase 3 data for an&nbsp;oral COVID-19 pill,&nbsp;molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.</p>\n<p>These two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.</p>\n<p><b>Pfizer Vs. Merck Data Comparison:</b>As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.</p>\n<p>Only about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.</p>\n<p>Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.</p>\n<p>Merck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.</p>\n<p>Through day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight&nbsp;deaths in patients who received placebo.</p>\n<p>Not only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.</p>\n<p>\"Between&nbsp;<b>Roche Holding AG's</b>&nbsp;recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.</p>\n<p><b>Authorization Before Year-End?</b>At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.</p>\n<p>It plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.</p>\n<p>BofA expects the application to be soon submitted to the FDA, with&nbsp;an authorization likely&nbsp;by the end of the year.</p>\n<p>Meanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.</p>\n<p>Its application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.</p>\n<p>The commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.</p>\n<p>Meanwhile,&nbsp;<b>Gilead, Inc.'s</b>&nbsp;antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.</p>\n<p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Pfizer Outgun Merck With Oral COVID-19 Pill?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Pfizer Outgun Merck With Oral COVID-19 Pill?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 08:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.benzinga.com/general/biotech/21/11/23925379/will-pfizer-outgun-merck-with-oral-covid-19-pill","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152406340","content_text":"Merck, Inc. is locking horns with peer Pfizer, Inc. in what could be termed as the battle supremacy in the COVID-19 treatment market.\nThe stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.\nPfizer Dips Into COVID-19 Treatment Arena:After acing the COVID-19 vaccine race along with its German partner BioNTech SE, Pfizer is wanting to leave no stone unturned in capitalizing on the COVID opportunity.\nThe company announced Friday an interim analysis of data from the Phase 2/3 study of its oral COVID-19 antiviral candidate Paxlovid, showing an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset.\nThe positive data triggered strong buying in Pfizer shares and a sell-off in Merck shares.\nMerck had its share of upside in early October when it reported positive Phase 3 data for an oral COVID-19 pill, molnupiravir, that it's co-developing the treatment with Ridgeback Biotherapeutics. The Merck news triggered an across-the-board sell-off in vaccine stocks at that time.\nThese two companies with deep pockets and marketing expertise are vying for a piece of the COVID-19 treatment market, making the competitive landscape all the more interesting.\nPfizer Vs. Merck Data Comparison:As opposed the 89% reduction in risk of hospitalization or death reported by Pfizer for Paxlovid, an interim analysis of Merck's Phase 3 data released on Oct. 1 showed molnupiravir reducing the risk of hospitalization or death by approximately 50%.\nOnly about 0.8% of patients who received Paxlovid were hospitalized through day 28 compared to 7% of patients who received placebo and were hospitalized or died.\nSimilar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset.\nMerck reported that 7.3% of patients who received molnupiravir were either hospitalized or died through day 29 compared with 14.1% of placebo-treated patients.\nThrough day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo. With Merck, through day 29, no deaths were reported in patients who received molnupiravir, as compared to eight deaths in patients who received placebo.\nNot only is Pfizer's drug safe, but the level of efficacy is so high that it will very meaningfully shake up the COVID landscape looking to next year— including the outlook for boosters, BofA Securities analyst Geoff Meacham said in a note.\n\"Between Roche Holding AG's recent failure and Merck's decent efficacy, Pfizer's drug will be the clear best-in-class oral, and well positioned to capitalize on the longer term C-19 treatment market that could be in the mid-to-high billions next year,\" Meacham said.\nAuthorization Before Year-End?At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results, the company said.\nIt plans to submit the data as part of its ongoing rolling submission to the authorization as soon as possible.\nBofA expects the application to be soon submitted to the FDA, with an authorization likely by the end of the year.\nMeanwhile, Merck announced Thursday it has received the first authorization for molnupiravir in the U.K., with the drug to be marketed under the brand name Lagevrio.\nIts application with the FDA is under review. The European Medicines Agency has recently initiated a rolling review of its Marketing Authorization Application. Merck also said it is actively working to submit applications to other regulatory agencies around the world.\nThe commercial outlook could dramatically shift in favor of Pfizer's pill given how much more impressive the data is, BofA said. Merck's revenue guidance of $5 billion to $7 billion through 2022 provided on its third-quarter call last week could be reduced meaningfully, the firm added.\nMeanwhile, Gilead, Inc.'s antiviral remdesivir could remain an option for hospitalized patients, but overall its use is likely to further diminish, in BofA's view.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848315844,"gmtCreate":1635967406960,"gmtModify":1635967407046,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>[What]&nbsp;","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>[What]&nbsp;","text":"$XPeng Inc.(XPEV)$[What]","images":[{"img":"https://static.tigerbbs.com/00698f2c640d8a3ddb153350c4465240","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848315844","isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843715943,"gmtCreate":1635858635247,"gmtModify":1635858635247,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>Upup","listText":"<a href=\"https://laohu8.com/S/XPEV\">$XPeng Inc.(XPEV)$</a>Upup","text":"$XPeng Inc.(XPEV)$Upup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843715943","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843716246,"gmtCreate":1635858494280,"gmtModify":1635858494280,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>👌","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>👌","text":"$Merck(MRK)$👌","images":[{"img":"https://static.tigerbbs.com/ad18d7da2125956cccdcd353332ec8df","width":"1125","height":"3083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843716246","isVote":1,"tweetType":1,"viewCount":643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849842735,"gmtCreate":1635745760453,"gmtModify":1635745760453,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849842735","repostId":"840102207","repostType":1,"repost":{"id":840102207,"gmtCreate":1635598740000,"gmtModify":1635601193973,"author":{"id":"3524105760314666","authorId":"3524105760314666","name":"华商韬略","avatar":"https://static.tigerbbs.com/fbcbbcdfdd125576e4d9038a38b0dc86","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"市值观察丨最强“她经济”！超级风口肥了谁？","htmlText":"作 者 / 文 雨 图片：网络、图虫创意 &nbsp; 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","listText":"作 者 / 文 雨 图片：网络、图虫创意 &nbsp; 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","text":"作 者 / 文 雨 图片：网络、图虫创意 来源：市值观察（ID：shizhiguancha） 过去几年，A股市场上的最强风口既不是芯片也不是新能源，而是HPV疫苗。 1 实事求是：短缺时代多疯狂 人们习惯于将HPV疫苗等同于宫颈癌疫苗，实际上这并不严谨。 HPV是一种DNA病毒，中文名为人**瘤病毒，HPV疫苗就是预防HPV病毒的疫苗，注射后可阻止HPV病毒感染。 HPV病毒感染是导致宫颈癌和**湿疣以及部分肛门癌、口腔癌的主要因素。临床发现，宫颈癌几乎全部是由于HPV感染引起的，所以HPV疫苗在很多时候直接被称为宫颈癌疫苗。 HPV是一个大家族，里面有约100多种不同习性的病毒亚型，按照覆盖HPV亚型的多少，目前活跃在市场上的HPV疫苗大致被分为二价、四价、九价三种。 二价HPV疫苗针对两种HPV亚型（16、18）；四价HPV疫苗针对四种HPV亚型（6、11、16、18）；九价HPV疫苗针对九种HPV亚型（6、11、16、18、31、33、45、52、58）。随着价数的增加，疫苗预防的有效率不断提升。 根据之前的研究数据，女性一生中感染HPV的几率高达80%，但大多数感染者属于“一过性”感染，最后能够自行痊愈。但如果发生持续性感染，则常常会在5年内发展到宫颈癌前病变。 高发病率使得发达国家对HPV疫苗格外重视，2013年，全美13-17岁女孩HPV疫苗接种率为37.6%，到2017年，这一数据提升到了63%。 2013年，日本政府将HPV疫苗纳入推荐列表，并免费提供疫苗接种服务。根据当时的数据统计，到2016年，1994年至1998年期间出生的日本女孩完成3次接种的比例高达70%。不过随后出现的群体性不良反应迫使日本政府暂停推荐HPV疫苗，在自愿接种的背景下，接种率直线下滑。 相比之下，中国的接种率则低的可怜，拿最为发达的上海地区来说，9-15岁女性的HPV","images":[{"img":"https://static.tigerbbs.com/1c06c03b7f3a46da8abbb2ef9e86d8a9","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/bb9d2414aeb240d38a1c9ccca1e3c0bf","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/8dd9ef57d2184ee4b4ab6f96012d242f","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/840102207","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849842859,"gmtCreate":1635745725267,"gmtModify":1635745725267,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Miser]&nbsp;[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MRK\">$Merck(MRK)$</a>[Miser]&nbsp;[Miser]&nbsp;","text":"$Merck(MRK)$[Miser] [Miser]","images":[{"img":"https://static.tigerbbs.com/c066cfaf8b4b464ede18b3861c3949ca","width":"1125","height":"2992"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849842859","isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849846435,"gmtCreate":1635745671828,"gmtModify":1635745671915,"author":{"id":"3582197285087556","authorId":"3582197285087556","name":"TKangWM","avatar":"https://static.tigerbbs.com/e6d5c7cfa41fb45c160ed7c4af893e54","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849846435","repostId":"2179229343","repostType":2,"isVote":1,"tweetType":1,"viewCount":399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}